Cantor Fitzgerald's Oncology, Hematology & HemeOnc Conference


NEW JERSEY and HANGZHOU, China, September 29, 2022-- Adlai Nortye Ltd. (“Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, announced that this week attended Cantor Fitzgerald's Oncology, Hematology & HemeOnc Conference.

Lars Birgerson, President of Adlai Nortye Ltd., discussed Adlai Nortye’s focus on the discovery and development of innovative cancer therapies for patients across tumor types, with multi-national R&D centers in both China and the United States. The company highlighted its most advanced drug buparlisib, a pan-PI3K inhibitor that is in a registrational trial in metastatic Head and Neck Squamous Cell Carcinoma. The company also highlighted the potential of its other pipeline drugs, palupiprant and AN4005, in solid tumors.